Amedisys Inc (NASDAQ:AMED) insider Michael Paul North sold 10,067 shares of the company’s stock in a transaction that occurred on Wednesday, July 24th. The stock was sold at an average price of $130.00, for a total transaction of $1,308,710.00. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.
Michael Paul North also recently made the following trade(s):
- On Thursday, July 18th, Michael Paul North sold 1,183 shares of Amedisys stock. The stock was sold at an average price of $130.00, for a total transaction of $153,790.00.
- On Wednesday, June 5th, Michael Paul North sold 5,248 shares of Amedisys stock. The stock was sold at an average price of $115.01, for a total transaction of $603,572.48.
AMED opened at $135.83 on Monday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.91 and a current ratio of 0.91. The company has a market capitalization of $4.35 billion, a P/E ratio of 37.42, a price-to-earnings-growth ratio of 1.69 and a beta of 1.34. The business’s 50 day simple moving average is $122.26. Amedisys Inc has a fifty-two week low of $92.08 and a fifty-two week high of $140.91.
A number of large investors have recently modified their holdings of the business. Riverbridge Partners LLC bought a new stake in Amedisys in the second quarter valued at approximately $80,465,000. Norges Bank bought a new stake in Amedisys in the fourth quarter valued at approximately $68,342,000. Geode Capital Management LLC increased its stake in Amedisys by 23.4% in the fourth quarter. Geode Capital Management LLC now owns 429,999 shares of the health services provider’s stock valued at $50,357,000 after purchasing an additional 81,573 shares in the last quarter. FMR LLC increased its stake in Amedisys by 13.4% in the first quarter. FMR LLC now owns 370,789 shares of the health services provider’s stock valued at $45,703,000 after purchasing an additional 43,844 shares in the last quarter. Finally, Deutsche Bank AG increased its stake in Amedisys by 12.1% in the fourth quarter. Deutsche Bank AG now owns 319,075 shares of the health services provider’s stock valued at $37,365,000 after purchasing an additional 34,553 shares in the last quarter. 88.52% of the stock is owned by hedge funds and other institutional investors.
A number of equities research analysts recently weighed in on AMED shares. ValuEngine raised shares of Zumiez from a “sell” rating to a “hold” rating in a research note on Saturday, June 22nd. BidaskClub downgraded shares of Zai Lab from a “strong-buy” rating to a “buy” rating in a research note on Friday. Raymond James downgraded shares of RioCan Real Estate Investment Trust to a “hold” rating in a research note on Monday, July 15th. Finally, Jefferies Financial Group set a $150.00 price target on shares of Amedisys and gave the stock a “buy” rating in a research note on Monday, July 8th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $131.74.
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.
See Also: What is systematic risk?
Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.